TOKYO, July 30 (Reuters) - Japan on Friday approved the administration of AstraZeneca Plc's (AZN.L) COVID-19 vaccine after a few months' pause due to fears about potential side effects, local media reported.
Regulators approved the shot in May but paused the deployment amid lingering concerns about blood clots. Japan has so far relied vaccines made by Pfizer Inc (PFE.N) and Moderna Inc (MRNA.O) in its inoculation push.
The Japanese government plans to limit the administration of AstraZeneca's vaccines to people aged 40 or over, according to the media.
Reporting by Makiko Yamazaki; Editing by Himani Sarkar
Our Standards: The Thomson Reuters Trust Principles.